Allurion Technologies reports Q1 EPS 11c, one estimate (30c)

Reports Q1 revenue $9.4M, one estimate $9.2M. As of March 31, 2024, cash and cash equivalents totaled $29.7 million. “Our strong performance in the first quarter was driven by continued growth in procedural volume, leading to our highest volume in any quarter to date,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “We believe this increase in procedural volume reflects the strong demand for the Allurion Program and demonstrates how we are poised to capitalize on the attention being paid to the obesity management space. In parallel, we improved our execution and increased efficiency across our operations, leading to a reduction in our quarterly cash burn and operating expenses by 62% and 43%, respectively, compared to the fourth quarter of 2023.”